Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 6/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
| ▸ | STK10 | O94804 | 1/20 | 0.34 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | USP1 | O94782 | 2/20 | 0.32 |
| ▸ | WDR48 | Q8TAF3 | 2/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.31 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4280084 | 0.78 | CYP1A2 (0.35) | HSD11B1LMNAL3MBTL1BACE1 | |
| SCHEMBL4284234 | 0.76 | AGPAT2 (0.34) | L3MBTL1 | |
| SCHEMBL4282261 | 0.72 | HSD11B1 (0.39) | HSD11B1TRPA1TRPM8TRPV1STK10 | |
| SCHEMBL4287050 | 0.72 | AGPAT2 (0.33) | — | |
| SCHEMBL4282527 | 0.69 | HSP90AA1 (0.34) | LMNA | |
| SCHEMBL4278355 | 0.66 | AGPAT2 (0.46) | — | |
| SCHEMBL4285066 | 0.63 | DYRK3 (0.35) | L3MBTL1 | |
| SCHEMBL2447801 | 0.60 | BACE1 (0.47) | HSD11B1TRPA1TRPM8TRPV1ACHE | |
| SCHEMBL2448730 | 0.59 | ACP1 (0.44) | HSD11B1TRPA1TRPM8TRPV1ACHE | |
| SCHEMBL30921795 | 0.58 | HDAC4 (0.35) | PDK2L3MBTL1BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099183-A1 | PYRIMIDINES AND USES THEREOF | CELL THERAPEUTICS, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-7419984-B2 | Pyrimidines and uses thereof | CELL THERAPEUTICS, INC. (US) | 2008-09-02 | — | — | US | disclosed |
| US-20040204386-A1 | Pyrimidines and uses thereof | CELL THERAPEUTICS, INC. | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204386-A1 | Pyrimidines and uses thereof | LPCAT3, LPCAT1, APRT | HSD11B1 3786/4885TRPA1 4147/4885TRPM8 3613/4885 |
| US-20090099183-A1 | PYRIMIDINES AND USES THEREOF | LPCAT3, LPCAT1, APRT | HSD11B1 3125/4885TRPA1 3724/4885TRPM8 3397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.